ROS1-crizotinib

Anjali Murali1, Anju Farsana A1, Sobha Subramaniam2

  • 1Department of Medical Oncology, Amrita Institute of Medical Science and Research Centre Amrita Vishwa Vidyapeetham Kochi India.

Respirology case reports
|September 25, 2024
PubMed
概括

本案例研究显示,一名患有晚期非小细胞肺癌 (NSCLC) 的患者对ROS1阳性NSCLC的向疗法crizotinib有显著的反应,持续超过94个月.